C. Light Technologies raises $2.5M seed round to commercialize first ever retinal eye-tracking device for neurodegenerative disease
Summary
Their proprietary tracking technology, paired with advanced analytics, is poised to redefine the neurodegenerative space - providing new hope for millions of people worldwide. Funding will enable the company to procure a design and manufacturing firm to turn their working prototype into the finalized commercial product and ultimately through 510(k) FDA clearance. Worldwide, millions of people suffer from neurodegenerative health conditions, including MS, Alzhiemer’s and Parkinson’s,” said Dr. Christy K. Sheehy, P.h.D., C. Light Technologies’ Co-Founder and CEO. With a device sensitivity down to 1 micron of movement, C. Light captures novel eye motion data to create a unique digital fingerprint of neurodegeneration. With an estimated 1M people in the United States diagnosed with multiple sclerosis and millions more around the world, C. Light Technologies has developed a novel solution for monitoring disease progression, therapeutic efficacy, and improving patient outcomes.